TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following:~  1. EASI of 12 or more~ 2. Greater than or equal to 10% of body surface area involvement~ 3. Diagnosed with AD at least 2 years prior~* Have a history of inadequate clinical response to other eczema treatments~Exclusion Criteria:~* Females who are pregnant or nursing~* Participants who do not agree to use adequate contraception~* Are currently experiencing or have a history of:~  * Skin conditions such as psoriasis or lupus erythematosus~ * Skin disease that requires frequent hospitalizations or intravenous treatment~ * Compromised immunity~* Serious illness that could interfere with study participation, or a clinically important deviation in physical examination, vital sign measurements, electrocardiograms, or abnormalities on laboratory tests~* Currently experiencing or have a history of:~  * Active or latent Tuberculosis or specific immunity disorders and infections~ * Malignancy or lymphoproliferative diseases in the last 5 years (or cervical, basal or squamous skin cancer re-occurrence in the last 3 years)~ * Human Immunodeficiency Virus (HIV)~ * Hepatitis B, Hepatitis C, or chronic liver disease~* Have received certain types of vaccinations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baricitinib (Type: EXPERIMENTAL): Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)
- Placebo (Type: PLACEBO_COMPARATOR): Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Extended Release Depression Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR~* Baseline depressive symptoms, assessed by means of HAM-D (21-item) score ≥20, and HAM-D item 1 score ≥2~Exclusion Criteria:~* Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder~* Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period~* Use of Clozapine within 28 days prior to enrollment or Clozapine non responders~* Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug~* An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter~* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine Extended Release (Type: EXPERIMENTAL): None
- Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patient with cancer regardless of the location~* Patient with specific treatment (chemotherapy +/- targeted therapy and / or radiotherapy, hormone therapy or surgery)~* Patient with Functional Iron Deficiency or absolute with or without anemia~* Having given written informed consent prior to any procedure related to the study.~Exclusion Criteria:~* Patient in a palliative situation not receiving specific treatment for their cancer~* Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations~* Patient with myeloproliferative disease~* Contraindication to treatments for iron deficiency and / or anemia~* Pregnant woman, parturient or nursing mothers~* Patient has no valid health insurance~* Disorder precluding understanding of trial information or informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm with Ferinject (Type: EXPERIMENTAL): Ferinject will be administered once at inclusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate for Attention Problems After Pediatric TBI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between ages of 6-17~* Sustained Moderate to Severe TBI~* TBI occurred at least 6 months prior to beginning the study~* TBI occurred no earlier than 5 years of age~* Positive endorsement of 6 out of 9 items on the Vanderbilt ADHD inattention or hyperactivity scale~Exclusion Criteria:~* History of developmental disability or mental retardation~* Current active participation in ADHD-related behavioral intervention~* History of psychiatric condition requiring an inpatient admission in past 12 months~* Actively taking medications with a contraindication to Concerta that cannot be discontinued~* Current use of stimulant medication or ADHD specific medications that cannot be discontinued~* Non-blunt head injury~* Family history of arrhythmia~* Pregnancy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate (Type: EXPERIMENTAL): The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
- Placebo (Type: PLACEBO_COMPARATOR): The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be able to understand, either orally or in writing, and be able to consent and complete the required assessments and procedures~2. Patient provides signed/dated Informed Consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization after receiving a full explanation of the extent and nature of the study.~3. Patient must be at least 18 years of age at the time of screening.~4. If female, patient must be surgically sterile, postmenopausal, or not pregnant or lactating and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose.~5. Patient meets American Society of Anesthesiologists (ASA) Physical Classification System status of P1 to P4.~Exclusion Criteria:~1. Patient has a history of allergic reaction or hypersensitivity to any anesthetic agent or opioid.~2. Patient does not meet nils per os (NPO) status per ASA guidelines or institution's guideline.~3. Patient has a Mallampati Classification Score of 4; OR a Mallampati Classification Score of 3 AND a thyromental distance ≤4 cm, or for any other reason has a difficult airway, in the opinion of the Investigator.~4. Patient has an abnormal, clinically significant 3-lead ECG finding at predosing period Day 0.~5. Patient has participated in an investigational drug study within 1 month prior to study start.~6. Patient is unwilling to adhere to pre- and postprocedural instructions.~7. Patient for whom the use of fentanyl citrate injection (fentanyl) is contraindicated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients undergoing total thyroidectomy or a totalisation thyroid procedure.~* Patients capable of understanding and able to understand the study.~* Values visually 2 and ICG 2~Exclusion Criteria:~* Parathyroid disease or prior parathyroidectomy~* Lack of informed consent~* Altered mental status of the patient.~* ICG values \<2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- New treatment (Type: EXPERIMENTAL): In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
- Standart treatment (Type: ACTIVE_COMPARATOR): In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supporting Decisions About Health Insurance to Improve Care for the Uninsured

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be without health insurance currently; or~* Must be enrolled in one of the ACA exchange plans in the past 1 year; and~* Must speak English~Exclusion Criteria:~* Currently has health insurance that was not provided by being enrolled in one of the ACA exchange plans in the past year~* Currently has health insurance that is provided through public insurance or private employer-based insurance~* Does not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Decision Aid (DA) (Type: EXPERIMENTAL): The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
- Control (Type: NO_INTERVENTION): Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:post-bronchodilator FEV1\<80% of predicted normal (ECSC) and a post-bronchodilator FEV1/FVC \<70% at Visit 1~2. Male or female patients, 40 years of age or older~3. Patients must be current or ex-smokers with a smoking history of more than 10 pack years:~Exclusion criteria:~1. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT \>x2 ULN, SGPT \>x2 ULN, bilirubin \>x2 ULN or creatinine \>x2 ULN~2. Patients with a history of asthma and/or total blood eosinophil count greater than 600/mm3~3. Patients with thyrotoxicosis, paroxysmal tachycardia (\>100 beats per minute)~4. Patients with a history of myocardial infarction within 1 year of screening visit, unstable or life-threatening cardiac arrhythmia, hospitalization for heart failure within the past year, known active tuberculosis, a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years, life-threatening pulmonary obstruction, cystic fibrosis, clinically evident bronchiectasis, significant alcohol or drug abuse~5. Patients who have undergone thoracotomy with pulmonary resection~6. Patients being treated with oral beta-adrenergics or oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.~7. Patients who regularly use daytime oxygen therapy for more than one hour per day.~8. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program~9. Pregnant or nursing women~10. Women of childbearing potential not using two effective methods of birth control (one barrier and one non-barrier).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI 1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from the Respimat inhaler
- Olodaterol (BI 1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from the Respimat inhaler
- Formoterol 12mcg (Type: ACTIVE_COMPARATOR): 12mcg inhaled twice daily from the Aerolizer inhaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age~* Essential hypertensive patients whose blood pressure is not controlled before the study (sit DBP ≥ 90 mmHg for drug-treated patient, sit DBP ≥ 95 mmHg for drug-naïve patient)~* Non-responder to 4 weeks treatment of amlodipine 5 mg monotherapy (sit DBP ≥ 90mmHg)~Exclusion Criteria:~* mean sit SBP ≥ 200 mmHg or mean sit DBP ≥ 120 mmHg at screening~* mean sit SBP ≥ 180 mmHg or mean sit DBP ≥ 120 mmHg after 4 weeks of amlodipine 5 mg treatment~* has a history of hypersensitivity to dihydropyridines or angiotensin II receptor blockers~* Secondary hypertensive patient or suspected to be~* Uncontrolled diabetes mellitus patients~* Severe heart disease or severe neurovascular disease~* Known as severe or malignant retinopathy~* Patients showed clinically significant hematological finding, patients with renal diseases (serum creatinine), patients with hepatic disease (ALT or AST)~* History of malignancy tumor~* History of autoimmune disease~* History of alcohol or drug abuse~* Positive to pregnancy test, nursing mother, has an intention on pregnancy~* Considered by investigator as not appropriate to participate in the clinical study with othe reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amlodipine/losartan 5/50mg (Type: EXPERIMENTAL): None
- amlodipine 5mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.~* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.~* Willing to comply with the study visits and requirements of the study protocol.~Exclusion Criteria:~* Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.~* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.~* Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.~* Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.~* Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
- CTP-543 8 mg BID (Type: EXPERIMENTAL): Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
- CTP-543 12 mg BID (Type: PLACEBO_COMPARATOR): Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Stress Urinary Incontinence Via Smartphone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stress urinary incontinence~* leakage once a week or more often~* duration of symptoms for at least 6 months~* motivation and time to perform a 12 week long treatment with pelvic floor muscle training~* ability to read and write Swedish~* asset to smartphone~* possibility to send and receive email and asset to printer~* accept to be randomized to one of two groups; a treatment group or a waiting list group~Exclusion Criteria:~* participation in our previous internet study~* pregnancy~* former incontinence surgery~* known malignancy in lower abdomen~* difficulties with passing urine~* visual blood in urine~* intermenstrual bleeding~* severe psychiatric diagnosis~* neurological disease with affection on sensibility in legs or lower abdomen~* urge incontinence

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Smartphone treatment (Type: ACTIVE_COMPARATOR): Smartphone treatment with PFMT.
- Waiting list (Type: NO_INTERVENTION): Waiting list for three months. They receive the smartphone application after follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by DSM-IV-TR criteria~* The current depressive episode must be equal to or greater than 8 weeks in duration~* Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than three adequate antidepressant treatments.~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.~* Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.~* Subjects with a current Axis I (DSM-IV-TR) diagnosis of:~  * Delirium, dementia,amnestic or other cognitive disorder~ * Schizophrenia, schizoaffective disorder, or other psychotic disorder~ * Bipolar I or II disorder~ * Subjects with a clinically significant current Axis II (DSM-IV-TR)~ * diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): OPC-34712 + ADT
- 2 (Type: PLACEBO_COMPARATOR): Placebo + ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete